Thorsby E, Pfeffer P, Leivestad T
Institute of Immunology, Rikshospitalet University Hospital, Oslo, Norway.
Transplant Proc. 2004 Mar;36(2 Suppl):16S-21S. doi: 10.1016/j.transproceed.2004.01.058.
HLA molecules are peptide-presenting molecules for T cells. T-cell receptors (TCR) recognize antigen-derived peptides bound to HLA molecules in cell membranes, namely, peptide-HLA (pHLA) complexes. An allograft will be recognized as foreign by recipient T cells via two slightly different mechanisms--direct and indirect allorecognition. In direct allorecognition, recipient T cells directly recognize foreign pHLA complexes on donor cells, in particular on donor dendritic cells (DC). In indirect allorecognition, recipient T cells recognize foreign peptides from the graft presented by self-HLA molecules on recipient DC. Cyclosporine (CsA) inhibits some activation signals in T cells as the result of allorecognition. Notwithstanding the strong immunosuppressive effects of CsA, reducing the degree of allorecognition through HLA matching is still of clinical significance. Data from our own transplant center and results from others demonstrate that the introduction of CsA as a main immunosuppressive drug does not nullify the significant beneficial effects of HLA matching on the frequency and strength of rejection episodes as well as on graft survival after allotransplantation. In cadaveric donor transplantation we observe significant effects of matching just for a limited number of (broad) HLA-DR molecules. We conclude that one should take advantage both of the strong immunosuppressive effects of CsA and other modern immunosuppressants as well as the beneficial effects of optimal HLA matching in clinical transplantation.
HLA分子是T细胞的肽呈递分子。T细胞受体(TCR)识别与细胞膜上HLA分子结合的抗原衍生肽,即肽-HLA(pHLA)复合物。同种异体移植物会通过两种略有不同的机制被受体T细胞识别为异物——直接和间接同种异体识别。在直接同种异体识别中,受体T细胞直接识别供体细胞上的外来pHLA复合物,特别是供体树突状细胞(DC)上的复合物。在间接同种异体识别中,受体T细胞识别由受体DC上的自身HLA分子呈递的来自移植物的外来肽。环孢素(CsA)作为同种异体识别的结果,抑制T细胞中的一些激活信号。尽管CsA具有强大的免疫抑制作用,但通过HLA配型降低同种异体识别程度仍具有临床意义。我们自己移植中心的数据以及其他研究结果表明,引入CsA作为主要免疫抑制药物并不能消除HLA配型对排斥反应的频率和强度以及同种异体移植后移植物存活的显著有益影响。在尸体供体移植中,我们观察到仅对有限数量(宽泛)的HLA-DR分子进行配型就有显著效果。我们得出结论,在临床移植中,应该同时利用CsA和其他现代免疫抑制剂的强大免疫抑制作用以及最佳HLA配型的有益效果。